Google Scholar | Citations: 16429| h-index: 32 | i10-index: 482
The progressive unfolding of aphasia: a diagnostic trajectory
PDF

Keywords

Frontotemporal dementia
Primary progressive aphasia
Alzheimer’s disease

How to Cite

The progressive unfolding of aphasia: a diagnostic trajectory. (2026). Electronic Journal Collection Health, 26(1), e22050. https://doi.org/10.25248/reas.e22050.2026

Copyright © | All rights reserved.

The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.

Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.

Total reproduction
It is expressly prohibited and must be authorized by the journal.

Abstract

Objective: To report a case of Frontotemporal Dementia Variant Primary Progressive Aphasia with agrammatism (FTD-PPA), a rare neurodegenerative disease that represents significant challenges in differential diagnosis, particularly with Alzheimer’s Disease (AD). Case detail: A 62-year-old female initially presented with amnesia, anxiety, and speech difficulties, managed with fluoxetine, resulting in partial improvement. Over three years, she exhibited progressive cognitive and functional decline, including mental confusion, aphasia, motor difficulties, and significant weight loss. Mini-Mental State Examination scores deteriorated from 20/30 to 9/30. The diagnosis was established by prioritizing the decisive cerebrospinal fluid biomarker evidence, which excluded AD, and the dominant clinical phenotype of progressive aphasia over the atypical neuroimaging findings. Management included antidepressants, donepezil (later discontinued), and speech therapy, with limited cognitive improvement despite mood stabilization. Final considerations: This case highlights the complexities of diagnosing progressive cognitive impairment. Comprehensive clinical, neuropsychological, and biomarker evaluations were critical in differentiating FTD-PPA from AD. The predominance of linguistic deficits and biomarker results confirmed the diagnosis of the agrammatic variant of FTD-PPA. Multidisciplinary follow-up and individualized symptom management were essential in optimizing the patient’s quality of life.

PDF

References

BELDER CRS, et al. Primary progressive aphasia: six questions in search of an answer. Journal of Neurology, 2024; 271: 1028–1046.

CHOW TW, MENDEZ MF. Goals in symptomatic pharmacologic management of frontotemporal lobar degeneration. American Journal of Alzheimer’s Disease & Other Dementias, 2002; 17(5): 267–272.

COYLE-GILCHRIST IT, et al. Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes. Neurology, 2016; 86: 1736–1743.

GORNO-TEMPINI ML, et al. Cognition and anatomy in three variants of primary progressive aphasia. Annals of Neurology, 2004; 55(3): 335–46.

GORNO-TEMPINI ML, et al. Classification of primary progressive aphasia and its variants. Neurology, 2011; 76(11): 1006–14.

HARDY CJ, et al. Symptom-led staging for primary progressive aphasia. MedRxiv, 2023.

JACK CR, et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology, 2016; 87(5): 539-47.

JACK CR, et al. Suspected non-Alzheimer disease pathophysiology--concept and controversy. Nature Reviews Neurology, 2016; 12(2): 117-24.

LAAKSO MP, et al. Hippocampus and entorhinal cortex in frontotemporal dementia and Alzheimer's disease: a morphometric MRI study. Biological Psychiatry, 2000; 47(12): 1056-63.

GUIMET NM, et al. Advances in Treatment of Frontotemporal Dementia. The Journal of Neuropsychiatry and Clinical Neurosciences, 2022; 34(4): 316–327.

MAGNIN E, et al. Initial neuropsychological profile of a series of 20 patients with logopenic variant of primary progressive aphasia. Journal of Alzheimer’s Disease, 2013; 36: 799–808.

MAGNIN E, et al. Primary progressive aphasia in the network of French Alzheimer Plan memory centers. Journal of Alzheimer's Disease, 2016; 54: 1459–1471.

MARSHALL CR, et al. Primary progressive aphasia: a clinical approach. Journal of Neurology, 2018; 265(6): 1474–90.

MESULAM M. Primary progressive aphasia: A dementia of the language network. Dementia & Neuropsychologia, 2013; 7(1): 2–9.

MOLINUEVO JL, et al. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer’s disease diagnosis: A consensus paper from the Alzheimer’s Biomarkers Standardization Initiative. Alzheimer’s & Dementia, 2014; 10(6): 808–17.

OLNEY NT, et al. Frontotemporal Dementia. Neurologic clinics, 2017; 35(2): 339–374.

PEET BT, et al. Neuroimaging in Frontotemporal Dementia: Heterogeneity and Relationships with Underlying Neuropathology. Neurotherapeutics, 2021; 18(2): 728-752.

RABINOVICI GD, MILLER BL. Frontotemporal lobar degeneration. CNS Drugs 2010; 24: 375–398.

REUTER M, et al. Head motion during MRI acquisition reduces gray matter volume and thickness estimates. NeuroImage, 2015; 117: 125–135.

RIZZI L, BALTHAZAR MLF. Mini-review: The suspected non-Alzheimer’s disease pathophysiology. Neuroscience Letters, 2021; 764: 136208.

SOUZA LC, et al. Biological markers of Alzheimer’s disease. Arquivos de Neuro-Psiquiatria, 2014; 72(3): 227–31.

VOS SJB, et al. The clinical importance of suspected non-Alzheimer disease pathophysiology. Nature Reviews Neurology, 2024; 20(6): 337–46.

WHITWELL J, JOSEPHS K. Neuroimaging in frontotemporal lobar degeneration—predicting molecular pathology. Nature Reviews Neurology, 2012; 8: 131–142.